• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Company filed SEC Form 8-K: Entry into a Material Definitive Agreement

    5/20/26 4:10:41 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email
    8-K
    Sotera Health Co false 0001822479 0001822479 2026-05-20 2026-05-20
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): May 20, 2026

     

     

    SOTERA HEALTH COMPANY

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Delaware   001-39729   47-3531161
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

    9100 South Hills Blvd, Suite 300

    Broadview Heights, Ohio 44147

    (Address of Principal Executive Offices) (Zip Code)

    (440) 262-1410

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading
    Symbol

     

    Name of Exchange

    on which registered

    Common stock, $0.01 par value per share   SHC   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01

    Entry into a Material Definitive Agreement.

    Credit Agreement

    On May 20, 2026, Sotera Health Company (the “Company”), Sotera Health Holdings, LLC (“SHH”), certain subsidiaries of the Company, each 2026 Refinancing Term Lender (the “Refinancing Lenders”) and JPMorgan Chase Bank, N.A., as first lien Administrative Agent (the “Administrative Agent”) entered into Amendment No. 7 (the “Amendment”) to the First Lien Credit Agreement dated as of December 13, 2019, by and among the Company, SHH, the Administrative Agent and the lenders and issuing banks party thereto (the “Credit Agreement”).

    Among other changes, the Amendment provides that the Refinancing Lenders will provide term loans (the “Repriced Term Loans”) to SHH in an aggregate principal amount of $1,415,914,725.62.

    The Amendment reduces the interest rate spread by 0.25% across term loans under the facility. The Repriced Term Loans shall have an applicable interest rate margin equal to Adjusted Term SOFR (as defined in the Credit Agreement) plus 2.25%, with a 0.00% floor (with optionality for the Company to elect Alternate Base Rate plus 1.25% or Adjusted Daily Simple SOFR plus 2.25% (each as defined in the Credit Agreement)).

    The Repriced Term Loans are also subject to a “soft call” premium of 1.00% for certain repricing transactions with respect to the Repriced Term Loans that occur within the six-month period after the effective date of the Amendment. The Repriced Term Loans amortize at a rate of 1.00% per annum and mature on May 30, 2031.

    The foregoing description of certain provisions of the Amendment and the underlying Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement and the Amendment, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The disclosure set forth under Item 1.01 above is incorporated herein by reference.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits:

     

    Exhibit

    No.

       Description
    10.1    Amendment No. 7, dated as of May 20, 2026, to the First Lien Credit Agreement dated as of December 13, 2019 by and among Sotera Health Company, Sotera Health Holdings, LLC, certain subsidiaries of Sotera Health Company, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent, and the 2026 Refinancing Term Lenders party thereto.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

       

    Sotera Health Company

       (Registrant)

    Date: May 20, 2026     By:  

    /s/ Jonathan M. Lyons

          Jonathan M. Lyons
          Senior Vice President and Chief Financial Officer
    Get the next $SHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    12/18/2025Outperform
    William Blair
    11/13/2025$19.00Outperform
    BMO Capital Markets
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    More analyst ratings

    $SHC
    SEC Filings

    View All

    SEC Form SD filed by Sotera Health Company

    SD - Sotera Health Co (0001822479) (Filer)

    5/29/26 4:05:15 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Sotera Health Co (0001822479) (Filer)

    5/22/26 4:09:28 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Company filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Sotera Health Co (0001822479) (Filer)

    5/20/26 4:10:41 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Klee Ann R. was granted 14,970 shares, increasing direct ownership by 12% to 140,926 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 8:27:22 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Chief Executive Officer Shader Alton was granted 579,573 shares (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 5:54:27 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 3 filed by new insider Shader Alton

    3 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 5:47:15 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sotera Health Announces Secondary Offering of Common Stock

    CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registra

    5/11/26 4:33:27 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

    Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025Q1 2026 Adjusted EBITDA(1) increased 10.5%, or 6.9% on a constant currency basisQ1 2026 Adjusted EPS(1) of $0.18, an increase of 29% per diluted shareCompany reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basisCompany announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Compan

    5/5/26 7:03:49 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Leadership Transition

    Alton Shader, CEO of Viant Medical®, to become CEO and join the Board of Directors, effective May 26, 2026Chairman and CEO Michael B. Petras, Jr. will serve as Executive Chairman of the Board of Directors CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced the appointment of Alton Shader to the role of Chief Executive Officer ("CEO") of the Company, effective May 26, 2026, as part of a planned leadership transition. Mr. Shader will succeed Michael B. Petras, Jr., Chair

    5/5/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sotera Health from Neutral to Overweight and set a new price target of $24.00

    1/9/26 8:33:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital Mkts resumed coverage on Sotera Health with a new price target

    RBC Capital Mkts resumed coverage of Sotera Health with a rating of Outperform and set a new price target of $24.00

    1/9/26 8:12:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    William Blair initiated coverage on Sotera Health

    William Blair initiated coverage of Sotera Health with a rating of Outperform

    12/18/25 9:11:03 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Appoints Richard Kyle to the Board of Directors

    CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle served as President and Chief Executive Officer of The Timken Company ("Timken") (NYSE:TKR), a global manufacturer of bearings, transmissions, and industrial motion produc

    2/5/26 7:30:00 AM ET
    $SHC
    $SON
    $TKR
    Misc Health and Biotechnology Services
    Health Care
    Containers/Packaging
    Consumer Discretionary

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    $SHC
    Financials

    Live finance-specific insights

    View All

    Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

    Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025Q1 2026 Adjusted EBITDA(1) increased 10.5%, or 6.9% on a constant currency basisQ1 2026 Adjusted EPS(1) of $0.18, an increase of 29% per diluted shareCompany reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basisCompany announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Compan

    5/5/26 7:03:49 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces First-Quarter 2026 Earnings Release Date

    CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2026 before the market opens on Tuesday, May 5, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's operating and financial results. A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company's website at Presentation & Event

    4/21/26 7:46:03 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

    2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

    2/24/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/12/24 5:53:58 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care